In the rapidly evolving field of antimicrobial therapy, a transformative shift is occurring with the advent of Bayesian dosing and therapeutic drug monitoring (TDM). These innovations are significantly impacting hospital resource allocation and patient care management. Dr. Sharmeen Roy, a leading authority in this field who serves as the chief strategy and science officer at DoseMe, offers insights into the prospective benefits and challenges of these advancements.
Traditionally, the management of antimicrobial therapy, particularly for drugs requiring TDM, has been a painstaking process. With surging patient volumes and constrained resources, a more streamlined, precise dosing approach has been imperative. This is where Bayesian dosing presents itself as a groundbreaking solution. Not only does it demonstrate considerable strength in the treatment of medications with a narrow therapeutic window, but it also navigates the challenges of resource allocation in a hospital environment effectively.
While vancomycin is the most frequently used antimicrobial in the DoseMe software, followed by aminoglycosides, it is important to note that the benefits of Bayesian dosing extend beyond these parameters. Tying complex pharmacokinetic calculations with an automated process, Bayesian dosing personalizes therapy for each patient. This methodology frees clinicians from intricate manual calculations, enabling them to focus on clinical judgment. As a result, patient care improves, leading to shorter hospital stays, a decrease in adverse events, and reduced toxicity risks.
Another advantage of Bayesian dosing is its ability to make the healthcare system more sustainable by conserving lab and nursing resources. As the software permits limited sampling, fewer lab tests are needed to optimize dosing, decreasing the workload for clinical pharmacists, nurses, and laboratory staff.
However, challenges remain in expanding Bayesian dosing beyond vancomycin to other antimicrobials, such as β-lactams and antifungals. The 2020 AUC-guided dosing guidelines have bolstered the case for Bayesian dosing, but still, the biggest hurdle lies in obtaining approval and support from hospital leadership.
Dr. Roy emphasizes that optimizing exposure levels of such treatments is crucial, backed by a clear shift in our understanding of these decades-old medications and their dosing strategies. Innovative tools like TDM are now augmenting treatment efficacy of drugs like β-lactams through precise dosing. With recent advancements in knowledge regarding lab breakpoints, bacterial targets, and dosing strategies, the effective and safe application of these treatments is becoming a reality.
The second part of this discussion will delve deeper into these advancements and the role of AI in precision dosing. Concurrent stories of interest in the sphere of infectious disease prevention will also be examined, including developments in diagnostics, phage therapy, and STIs home tests.